Primary results from a phase 2a study of zanidatamab (zani) plus palbociclib (palbo) plus fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)

被引：1
|
作者：
Escriva-de-Romani, Santiago
Cejalvo, Juan Miguel
Alba, Emilio
Friedmann, Jennifer
Lescure, Alvaro Rodriguez
Savard, Marie-France
Pezo, Rossanna C.
Gion, Maria
-Borrego, Manuel Ruiz
Hamilton, Erika
Pluard, Timothy
Webster, Marc
Beeram, Muralidhar
Linden, Hannah
Saura, Cristina
Shpektor, Diana
Salim, Bob
Harvey, Phoebe
Hurvitz, Sara
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-LBO1-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBO1-04
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Treatment of HER2-positive (HER2+) hormone-receptor positive (HR plus ) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant
    Escriva-De-Romani, Santiago
    Alba, Emilio
    Rodriguez-Lescure, Alvaro
    Hurvitz, Sara
    Cejalvo, Juan Miguel
    Gion, Maria
    Ferrario, Cristiano
    Borrego, Manuel Ruiz
    Pezo, Rossanna C.
    Hamilton, Erika
    Webster, Marc
    Pluard, Timothy
    Beeram, Muralidhar
    Rodriguez, Begona Jimenez
    Linden, Hannah
    Saura, Cristina
    Omidpanah, Adam
    Harvey, Phoebe
    Savard, Marie-France
    CANCER RESEARCH, 2023, 83 (05)
  • [2] Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis
    Chen, Dongshao
    Xu, Fei
    Lu, Yongkui
    Xia, Wen
    Du, Caiwen
    Xiong, Dun
    Song, Dong
    Shi, Yanxia
    Yuan, Zhongyu
    Zheng, Qiufan
    Jiang, Kuikui
    An, Xin
    Xue, Cong
    Huang, Jiajia
    Bi, Xiwen
    Chen, Meiting
    Zhang, Jingmin
    Wang, Shusen
    Hong, Ruoxi
    NPJ BREAST CANCER, 2024, 10 (01)
  • [3] Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC)
    Oliveira, Mafalda
    Bardia, Aditya
    Kim, Sung-Bae
    Niikura, Naoki
    Hernando, Cristina
    Werutsky, Gustavo
    Antill, Yoland
    Liedke, Pedro
    Oakman, Catherine
    Tokunaga, Eriko
    Wander, Seth
    Krause, Vanessa
    Yamashita, Toshinari
    Schimmoller, Frauke
    Rotmensch, Jacob
    Savage, Heidi
    Sane, Rucha
    Turner, Nicholas
    CANCER RESEARCH, 2022, 82 (04)
  • [4] A phase I/Ib study evaluating GDC-0077+palbociclib (palbo) plus fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Bedard, Philippe L.
    Jhaveri, Komal
    Cervantes, Andres
    Gambardella, Valentina
    Hamilton, Erika
    Italiano, Antoine
    Kalinsky, Kevin
    Krop, Ian E.
    Oliveira, Mafalda
    Saura, Cristina
    Schmid, Peter
    Turner, Nicolas
    Varga, Andrea
    Hutchinson, Katherine E.
    Lei, Guiyuan
    Royer-Joo, Stephanie
    Thomas, Piia
    Schutzman, Jennifer L.
    Juric, Dejan
    CANCER RESEARCH, 2021, 81 (04)
  • [5] Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer
    Guarneri, Valentina
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (11) : 1549 - 1557
  • [6] A phase II trial assessing the safety of an alternative dosing schedule of palbociclib (palbo) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC): Alt Dose Palbo
    Krishnamurthy, Jairam
    Luo, Jingqin
    Ademuyiwa, Foluso
    Suresh, Rama
    Rigden, Caron
    Reardon, Timothy
    Weilbaecher, Katherine
    Frith, Ashley
    Roshal, Anna
    Tandra, Pavan
    Cherian, Mathew
    Summa, Tracy
    Thomas, Shana
    Hernandez-Aya, Leonel
    Peterson, Lindsay
    Ma, Cynthia
    CANCER RESEARCH, 2020, 80 (04)
  • [7] Real-world study of patients with HR+/ HER2-metastatic breast cancer treated with palbociclib and fulvestrant
    Robert, Nicholas
    Chen, Connie
    Doan, Justin
    Venkatasetty, Divea
    Espirito, Janet L.
    Aguilar, Kathleen M.
    FUTURE ONCOLOGY, 2025, 21 (01) : 83 - 94
  • [8] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
    Rugo, H.
    Tolaney, S.
    Dickler, M.
    Kabos, P.
    Ho, C-L
    Wildiers, H.
    Jerusalem, G.
    Ales-Martinez, J. E.
    Hossain, A.
    Johnston, E.
    Gianni, L.
    CANCER RESEARCH, 2017, 77
  • [9] Palbociclib Plus Fulvestrant as First-Line Therapy for Patients with Locally Advanced, Inoperable or Metastatic HR+/HER2-Breast Cancer in Germany: Interim Results of the Inge-B Phase 2 Study
    Welt, Anja
    Welslau, Manfred
    Lueftner, Diana
    Deryal, Mustafa
    Liersch, Ruediger
    Sahlmann, Joerg
    Houet, Leonora
    Potthoff, Karin
    Marschner, Norbert
    Vannier, Corinne
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 13 - 14
  • [10] Palbociclib plus endocrine therapy in HR+/HER2-advanced breast cancer patients: Interim results of the PERFORM study
    Radosa, J. C.
    Fietz, T.
    Wilke, J.
    Decker, T.
    Petersen, V.
    Deryal, M.
    Knoblich, J.
    Losem, C.
    Rhein, U.
    Schoettker, B.
    Wrobel, D.
    Pfeiler, G.
    Zanucco, E.
    Buncke, J.
    Woerner, S.
    Gratzke, K.
    Adams, A.
    Glastetter, E.
    Bartsch, R.
    Lux, M. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S353 - S354
12345